Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

Abstract

Special (lipid) delivery: The role of the ionizable lipid pK(a) in the in vivo delivery of siRNA by lipid nanoparticles has been studied with a large number of head group modifications to the lipids. A tight correlation between the lipid pK(a) value and silencing of the mouse FVII gene (FVII ED(50) ) was found, with an optimal pK(a) range of 6.2-6.5. The most potent cationic lipid from this study has ED(50) levels around 0.005 mg kg(-1) in mice and less than 0.03 mg kg(-1) in non-human primates.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 18

1. 1.

   De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Nat. Rev. Drug Discovery. 2007;6:443-453.

   Not in our library10.1038/nrd2310

2. 2.

   Akhtar S, Benter IF. J. Clin. Invest. 2007;117:3623-3632.

   Not in our library10.1172/jci33494

3. 3.

   Whitehead KA, Langer R, Anderson DG. Nat. Rev. Drug Discovery. 2009;8:129-138.

   Not in our library10.1038/nrd2742

4. 4.

   Zimmermann TS, et al. Nature. 2006;441:111-114.

   Not in our library10.1038/nature04688

5. 5.

   Semple SC, et al. Nat. Biotechnol. 2010;28:172-176.

   Not in our library10.1038/nbt.1602

6. 6.

   Akinc A, Goldberg M, Qin J, Dorkin JR, Gamba-Vitalo C, Maier M, Jayaprakash KN, Jayaraman M, Rajeev KG, Manoharan M, Koteliansky V, Rohl I, Leshchiner ES, Langer R. Mol. Ther. 2009;17:872-879.

   Not in our library10.1038/mt.2009.36

7. 7.

   Heyes J, Palmer L, Bremner K, MacLachlan I. J. Controlled Release. 2005;107:276-287.

   Not in our library10.1016/j.jconrel.2005.06.014

8. 8.

   Bailey AL, Cullis PR. Biochemistry. 1994;33:12573-12580.

   Not in our library10.1021/bi00208a007

9. 9.

   Eastman SJ, Hope MJ, Cullis PR. Biochemistry. 1991;30:1740-1745.

   Not in our library10.1021/bi00221a002

10. 10.

    Zhang J, Fan H, Levorse DA, Crocker LS. Langmuir. 2011;27:1907-1914.

    Not in our library10.1021/la104590k

11. 11.

    Hafez IM, Maurer N, Cullis PR. Gene Ther. 2001;8:1188-1196.

    Not in our library10.1038/sj.gt.3301506

12. 12.

    Akinc A, et al. Mol. Ther. 2010;18:1357-1364.

    Not in our library10.1038/mt.2010.85

13. 13.

    Yan X, Kuipers F, Havekes LM, Havinga R, Dontje B, Poelstra K, Scherphof GL, Kamps JA. Biochem. Biophys. Res. Commun. 2005;328:57-62.

    Not in our library10.1016/j.bbrc.2004.12.137

14. 14.

    Zelphati O, Szoka FC. J. Liposome Res. 1997;7:31-49.

    Not in our library

15. 15.

    Demaurex N. News Physiol. Sci. 2002;17:1-5.

    Not in our library10.1152/physiologyonline.2002.17.1.1

16. 16.

    Kurosawa T, Igarashi S, Nishizawa M, Onodera O. Biochem. Biophys. Res. Commun. 2005;337:1012-1018.

    Not in our library10.1016/j.bbrc.2005.09.142

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    Simon A.

    Not in our library

Cited by papers we hold 40

• Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines · 2025
  No notice
• Nucleic acid drugs: recent progress and future perspectives · 2024
  No notice
• Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis · 2023
  No notice
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models · 2022
  No notice
• Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo · 2022
  No notice
• mRNA-based therapeutics: powerful and versatile tools to combat diseases · 2022
  No notice
• Cancer vaccines as promising immuno-therapeutics: platforms and current progress · 2022
  No notice
• Advances in COVID-19 mRNA vaccine development · 2022
  No notice
• Recent Advances in Lipid Nanoparticles for Delivery of mRNA · 2022
  No notice
• Payload distribution and capacity of mRNA lipid nanoparticles · 2022
  No notice
• mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability · 2021
  No notice
• Delivery of oligonucleotide‐based therapeutics: challenges and opportunities · 2021
  No notice
• Membrane‐destabilizing ionizable lipid empowered imaging‐guided siRNA delivery and cancer treatment · 2021
  No notice
• Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles · 2021
  No notice
• Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration · 2021
  No notice
• An ionizable lipid toolbox for RNA delivery · 2021
  No notice
• A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery · 2021
  No notice
• Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale · 2021
  No notice
• Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles · 2021
  No notice
• Nanomaterial Delivery Systems for mRNA Vaccines · 2021
  No notice

and 20 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.